The rational design of biomedical prevention approaches to block HIV infection requires a better understanding of early events in HIV infection, particularly the viral and host factors that reduce acquisition and/or slow disease progression. Our research team is in a unique position to examine these questions during HIV infection because we have developed and maintained a cohort of ~ 2500 women at high-risk of HIV infection since 1993. This cohort includes >300 women who have known dates of HIV infection and who have been followed closely, including regular sample collection and clinical monitoring prior to and for many years after HIV infection. In addition, 21 women who have acquired a second HIV infection (superinfection) have been identified. Thus, in this cohort, susceptibility to infection can be detected as acquisition of a first HIV infection, acquisition of multiple variants from a single source partner and acquisition of a second infection. We propose to study HIV acquisition in this way because it allows us to gain the most comprehensive view of the biological factors that impact women's risk of HIV acquisition. Superinfection specifically offers the rare opportunity to examine immune mechanisms of protection by defining deficits in the immune responses in those who become superinfected compared to those with similar risk profiles who do not. Information on an immune correlate in this setting would provide critical insights for vaccine design and for monitoring of immune markers in vaccine trials, which currently is based primarily on information from model systems, not human studies. In the current grant, we propose to take advantage of this one of a kind, 20-year cohort study to address three aims that build on and leverage our recent findings. These include comprehensive studies of viral and host factors that impact the risk of acquisition as well as HIV disease progression in both singly and superinfected women.., We will also define deficits in HIV imnnunity that are associated with HiV superinfection, providing key^insight into immune responses tl:iat are needed foran effective HIV vaccine. ,. ,; .,.,

Public Health Relevance

These studies are designed to identify factors that influence HIV clinical outcome in women and to determine the factors that impact the risk of HIV acquisition, particularly in the case of superinfection. A better understanding of what puts women at risk for HIV infection and disease is critical to designing effective biomedical interventions, including vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI038518-23
Application #
9232961
Study Section
Special Emphasis Panel (NSS)
Program Officer
Mcdonald, David Joseph
Project Start
1995-09-15
Project End
2020-02-29
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
23
Fiscal Year
2017
Total Cost
$789,642
Indirect Cost
$234,938
Name
Fred Hutchinson Cancer Research Center
Department
Type
Research Institutes
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Williams, Katherine L; Wang, Bingjie; Arenz, Dana et al. (2018) Superinfection Drives HIV Neutralizing Antibody Responses from Several B Cell Lineages that Contribute to a Polyclonal Repertoire. Cell Rep 23:682-691
Roberts, Sarah T; Flaherty, Brian P; Deya, Ruth et al. (2018) Patterns of Gender-Based Violence and Associations with Mental Health and HIV Risk Behavior Among Female Sex Workers in Mombasa, Kenya: A Latent Class Analysis. AIDS Behav 22:3273-3286
Heffron, Renee; McClelland, R Scott; Balkus, Jennifer E et al. (2017) Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. Lancet HIV 4:e449-e456
Ronen, Keshet; Dingens, Adam S; Graham, Susan M et al. (2017) Comprehensive Characterization of Humoral Correlates of Human Immunodeficiency Virus 1 Superinfection Acquisition in High-risk Kenyan Women. EBioMedicine 18:216-224
Doria-Rose, Nicole A; Altae-Tran, Han R; Roark, Ryan S et al. (2017) Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathog 13:e1006148
LaCourse, Sylvia M; Deya, Ruth W; Graham, Susan M et al. (2017) Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 76:74-81
Boyd, David F; Sharma, Amit; Humes, Daryl et al. (2016) Adapting SHIVs In Vivo Selects for Envelope-Mediated Interferon-? Resistance. PLoS Pathog 12:e1005727
McClelland, R Scott; Richardson, Barbra A; Cherutich, Peter et al. (2015) A 15-year study of the impact of community antiretroviral therapy coverage on HIV incidence in Kenyan female sex workers. AIDS 29:2279-86
Meyerson, Nicholas R; Sharma, Amit; Wilkerson, Gregory K et al. (2015) Identification of Owl Monkey CD4 Receptors Broadly Compatible with Early-Stage HIV-1 Isolates. J Virol 89:8611-22
Cortez, Valerie; Wang, Bingjie; Dingens, Adam et al. (2015) The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection. PLoS Pathog 11:e1004973

Showing the most recent 10 out of 88 publications